carbidopa and istradefylline

carbidopa has been researched along with istradefylline in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Jackson, MJ; Jenner, P; Kanda, T; Kase, H; Kuwana, Y; Nakamura, J; Pearce, RK; Smith, LA	1
Bara-Jimenez, W; Bibbiani, F; Chase, TN; Dimitrova, T; Favit, A; Gillespie, M; Morris, MJ; Mouradian, MM; Sherzai, A	1

Trials

1 trial(s) available for carbidopa and istradefylline

Article	Year
Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology, 2003, Aug-12, Volume: 61, Issue:3 Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Purines; Safety; Treatment Outcome	2003

Article

Year

Adenosine A(2A) receptor antagonist treatment of Parkinson's disease.

Neurology, 2003, Aug-12, Volume: 61, Issue:3

Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Purines; Safety; Treatment Outcome

2003

Other Studies

2 other study(ies) available for carbidopa and istradefylline

Article	Year
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Experimental neurology, 2000, Volume: 162, Issue:2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Callithrix; Carbidopa; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Injections, Intraperitoneal; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Purinergic P1 Receptor Antagonists; Purines; Quinpirole; Receptor, Adenosine A2A; Receptors, Dopamine D1; Receptors, Dopamine D2	2000
Istradefylline (Nourianz) for Parkinson's disease. The Medical letter on drugs and therapeutics, 2020, Feb-10, Volume: 62, Issue:1591 Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Drug Administration Schedule; Humans; Levodopa; Parkinson Disease; Purines	2020

Article

Year

Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.

Experimental neurology, 2000, Volume: 162, Issue:2

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Callithrix; Carbidopa; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Injections, Intraperitoneal; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Purinergic P1 Receptor Antagonists; Purines; Quinpirole; Receptor, Adenosine A2A; Receptors, Dopamine D1; Receptors, Dopamine D2

2000

Istradefylline (Nourianz) for Parkinson's disease.

The Medical letter on drugs and therapeutics, 2020, Feb-10, Volume: 62, Issue:1591

Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Drug Administration Schedule; Humans; Levodopa; Parkinson Disease; Purines

2020